C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The Company is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
企業コードCCCC
会社名C4 Therapeutics Inc
上場日Oct 02, 2020
設立日2015
最高経営責任者「CEO」Mr. Andrew J. Hirsch
従業員数110
証券種類Ordinary Share
決算期末Oct 02
本社所在地490 Arsenal Way
都市WATERTOWN
証券取引所NASDAQ Global Select Consolidated
国United States of America
郵便番号02472
電話番号16172310700
ウェブサイトhttps://c4therapeutics.com/
企業コードCCCC
上場日Oct 02, 2020
設立日2015
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし